# Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

> **NCT00529035** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 29 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT00529035
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2011-06
- **Final completion:** 2020-05-27
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529035, "Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00529035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*